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Etiological research aims to investigate the causal
relationship between putative risk factors (or determinants)
and a given disease or other outcome. In contrast, prognostic
research aims to predict the probability of a given clinical
outcome and in this perspective the pathophysiology of the
disease is not an issue. Multivariate modeling is a
fundamental tool both to infer causality and to investigate
prognostic factors in epidemiological research. The analytical
approaches to etiological and prognostic studies are strictly
dependent on the research question and imply knowledge of
the main statistical procedures for model building and data
interpretation. In this paper we describe the application of
multivariate statistical modeling in etiological and prognostic
research. We will mainly focus on the differences in model
building and data interpretation between these two areas of
epidemiologic research.
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In two previous papers of this series we described linear,
logistic, and Cox regression analyses1–2 as fundamental tools
for investigating the relationship between exposure to risk
factors and clinical outcomes. According to the research
question being addressed, statistical models can be used to
test both etiological (that is to infer causality) and prognostic
hypotheses (that is to predict a given clinical outcome). In
etiological research we are interested in determining the
presence or absence of a presumed causal relationship
between a putative risk factor and a specific clinical condition
and in this particular perspective confounding and previous
knowledge of the pathophysiology of the disease play a
fundamental role. In descriptive prognostic research we aim
at predicting the risk (that is the probability) of disease
without any concern about causality and confounding.
ETIOLOGICAL MODELS
Statistical modeling in etiological research
Multivariate modeling in etiological research may serve two
scopes: to adjust for confounders when confounders are
variables not in the same causal pathway leading to a given
outcome and to adjust for variables within a certain causal
pathway to unravel mechanisms (see below). Framingham
study investigators were the first to apply statistical modeling
to the study of complex (multifactorial) diseases like
hypertension or atherosclerosis. What matters in etiological
research is establishing the causal involvement of one or more
risk factors in a given disease. Thus, when we are to test the
association of a putative risk factor, for example obesity, as a
cause of coronary heart disease, it is fundamental that we
establish whether the association between this factor and the
outcome (for example incident myocardial infarction) is
independent of other confounding risk factors. To this end
we construct statistical models including all risk factors
whose causal role in determining the outcome is reasonably
well demonstrated. Otherwise stated, we set up an experi-
ment where we control by multivariate analysis all possible
sources of confounding.3 In this perspective, in the process of
selecting potential confounders, particular attention is
needed to make sure that the variable in question, rather
than a confounder, represents a factor in the same chain of
events leading to the outcome. For instance, insulin resistance
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is a well-recognized effect of overweight/obesity. If we adjust
the analysis for insulin resistance we may reduce or even
cancel out the link between obesity and myocardial
infarction. Therefore, we should not include measures of
insulin sensitivity into the multivariate model testing obesity
as a causal factor for myocardial infarction. On the other
hand, if we are interested to understand mechanisms, that is
to establish whether obesity induced by mechanisms other
than insulin resistance determines myocardial infarction,
then adjustment for insulin resistance may assist to explore
this hypothesis. Similarly in an animal study testing whether
obesity may cause cardiovascular (CV) damage by mechan-
isms other than insulin resistance, three interventions can be
compared: a control intervention (that is a normal calorie
diet), a high calorie diet (that makes normal animals obese
and insulin resistant), and the same diet administered to
genetically modified animals which maintain normal insulin
sensitivity while developing obesity. Of course the three
groups are matched for relevant baseline variables such as age
and sex. In this experiment the investigator is ideally poised
for isolating the effect of obesity and insulin resistance on the
CV system because all factors, but the interventions, are
equalized among experimental groups. Similarly, in epide-
miologic research we isolate the effect of the exposure/non
exposure to the risk factor in question (obesity vs normal
weight, insulin resistance vs normal insulin sensitivity) by
adjusting for the confounding effect of other risk factors (age,
sex, smoking, and others).
Example 1. In the nineties, it was hypothesized that
subclinical Chlamydia pneumoniae infection is a risk factor
for CV disease. Observations in chronic ambulatory perito-
neal dialysis (CAPD) patients specifically implicated this
pathogen in the high risk of death of these patients.4 As this
study was relatively small and could not adequately control
for confounding factors, the problem was re-examined in a
cohort study in 227 end-stage renal disease (ESRD) patients.5
To analyze the results of the study, the authors divided
patients into three groups on the basis of immunoglobulin A
(IgA) anti-Chlamydia antibody titer (from seronegativity to
high levels) and investigated the etiological role of Chlamydia
infection for all-cause and CV mortality by Cox regression
analysis (Table 1).2
During the follow-up, 102 patients died, 68% of them of
CV causes. On univariate Cox regression analysis (Table 1),
there was an IgA anti-Chlamydia titer-dependent increase in
the risk of all-cause and CV mortality so that patients with a
high titer (X1:16) displayed a significantly higher risk of all-
cause (hazard ratio: 1.89; excess risk: þ 89%) and CV
mortality (hazard ratio: 1.77, excess risk: þ 77%) when
compared to seronegative patients. If Chlamydia infection is
causally involved in the high risk of death in ESRD
population the relationship between IgA anti-C. pneumoniae
titer and all-cause and CV death should be unconfounded,
that is independent of other risk factors. In this study, age
and smoking appeared to be potential confounders3 for the
interpretation of the link between Chlamydia and clinical
outcomes because they were related to both IgA anti-
Chlamydia titer (the exposure) and to all-cause and CV
mortality (the outcomes). The independent association
between Chlamydia infection and all-cause and CV mortality
was therefore tested in Cox’s models adjusting for age and
smoking (Table 2).
After adjustment for age and smoking the hazard ratio for
all-cause and CV mortality became not significant and
reduced by 36% (from 1.89 to 1.21) and by 34% (from 1.77
to 1.16), respectively indicating a relevant degree of
confounding by these risk factors. Thus, age and smoking
engendered ‘positive confounding’, that is they determined an
overestimation of the risk associated with Chlamydia
infection. In other words, the reason why ESRD patients
exposed to high IgA anti-Chlamydia titer had an almost
twofold increase in the risk of death when compared to
seronegative patients was in a large part explained by the fact
that these patients were older and more frequently smokers as
compared to seronegative patients.
Example 2. The relationship between an endogenous
inhibitor of nitric-oxide synthase, asymmetrical dimethylar-
ginine (ADMA), and the risk of all-cause mortality and fatal
and non-fatal CV events was investigated in a cohort of 225
hemodialysis patients followed-up for an average time of
33±15 months.6 The study population was divided into
three groups according to 50th and 75th percentile of plasma
ADMA and the relationship between ADMA and study
outcomes was preliminarily investigated by univariate (un-
adjusted) Cox regression analysis (Table 3).
Table 1 | Univariate Cox regression analysis of IgA anti-
Chlamydia titer for all-cause and CV mortality
All-cause mortality CV mortality
Hazard ratio, 95% CI
and P-value
Hazard ratio, 95% CI
and P-value
IgA anti-Chlamydia titer
Seronegative 1a 1a
IgA titer 1:8 1.22 (0.64–2.34), P=0.55 1.65 (0.82–3.34), P=0.16
IgA titer X1:16 1.89 (1.25–2.87), P=0.003 1.77 (1.05–2.98), P=0.03
IgA, immunoglobulin A; CV, cardiovascular.
aReference group.
Table 2 | Multiple Cox regression analysis of IgA anti-
Chlamydia titer for all cause and CV mortality
All-cause mortality CV mortality
Hazard ratio, 95% CI
and P value (adjusted
for age and sex)
Hazard ratio, 95% CI
and P value (adjusted
for age and sex)
IgA anti-Chlamydia titer
Seronegative 1a 1a
IgA titer 1:8 1.03 (0.54–2.00), P=0.92 1.40 (0.69–2.85), P=0.36
IgA titer X 1:16 1.21 (0.79–1.87), P=0.39 1.16 (0.68–1.98), P=0.58
Age (1 year) 1.05 (1.03–1.07), Po0.001 1.05 (1.03–1.07), Po0.001
Smoking (yes/no) 1.90 (1.27–2.85), P=0.002 2.24 (1.38–3.65), P=0.001
IgA, immunoglobulin A; CV, cardiovascular.
aReference group.
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Univariate Cox regression analysis (Table 3) showed that
the overall risk of death and fatal and non-fatal CV events was
progressively higher from the 50th percentile onwards. This
biological gradient suggests that plasma ADMA is causally
implicated in adverse clinical outcomes in ESRD patients. To
confirm the study hypothesis, the authors identified a series
of potential confounders and constructed Cox regression
models of increasing complexity. Here we report only the
results of a model adjusting for age and sex (Table 4).
After data adjustment for age and sex, the hazard ratios for
death and CV events of plasma ADMA 475th percentile
became higher (3.11 and 2.80, respectively) than the
corresponding unadjusted (crude) estimates (2.43 and 2.41,
respectively) and these results were little influenced by further
adjustment for a large series of potential confounders (data
not shown).6 In this case, age and sex engendered ‘negative
confounding’, that is the confounding effect of these variables
resulted in an underestimation of the true hazard ratio of
plasma ADMA.
Multivariate modeling and causality. The problem of
causality can rarely, if ever, be resolved only on the basis of
well performed epidemiological studies or just on the basis of
biological experiments. Indeed, establishing the nature of a
given relationship (causal vs non causal) is a multidimen-
sional process demanding not only accordance with a large a
series of criteria (Table 5). Rothman and Greenland7 nicely
illustrate the imperfection of these criteria considered in an
isolated manner and carefully emphasize the importance of
detailed knowledge on pathophysiological pathways in the
assessment of causality.
In summary, the problem of causality in biomedical
research almost always demands application of various kind
of studies, that is experimental and observational studies as
well. Multivariate modeling of results of well-performed
epidemiological studies provides valuable information for
assessing the potential causal role of putative risk factors in
human diseases.
DESCRIPTIVE PROGNOSTIC MODELS
As previously discussed, in etiological research we aim to
establish if a presumed causal relationship between a given
risk factor and a given clinical outcome is unconfounded and
therefore we pay careful attention to excluding the influence
of confounding factors on the link being investigated. In
contrast with etiological studies where we try to control for
all possible confounding factors, in prognostic research we
simply aim at establishing the probability of a given outcome
and whether a given risk factor improves our prediction. As a
consequence, the nature (causal or non causal) of risk factors
being considered is not at issue.
Example 3. Left ventricular mass depends on a variety of
risk factors like blood pressure, body mass, hemoglobin
concentration, sympathetic activity, and other factors.
Independently of the causes that may generate it, left
ventricular hypertrophy is considered as one of the strongest
predictors of death and CV complications and it is formally
recommended by current guidelines for risk assessment
refinement in hypertensive patients. To test whether left
ventricular hypertrophy is useful for prognosis in the dialysis
population, a prospective cohort study in 254 dialysis
patients was performed.8 On crude (unadjusted) analysis a
10 g increase in left ventricular mass predicted a 45% increase
in the risk of death (Table 6). To assess whether LV mass adds
prognostic power for death to standard risk factors,
investigators built up a multivariate Cox model including
significant death predictors in the study population (that is
age, gender, cholesterol, albumin, previous CV events, and
C-reactive protein (CRP)) as well as left ventricular mass
index (LVMI). In this model, LVMI maintained a significant
prognostic value for all cause mortality and 10 g increase in
Table 3 | Univariate Cox regression analysis of plasma ADMA
for all-cause mortality and fatal and non-fatal CV events
All-cause mortality
Fatal and non-fatal
cardiovascular events
Hazard ratio, 95% CI
and P-value
Hazard ratio, 95% CI
and P-value
Plasma ADMA
o50th percentile
(o0.95 mmol/l)
1a 1a
50–75th percentile
(0.95–1.53mmol/l)
1.39 (0.81–2.39), P=0.23 1.94 (1.13–3.31), P=0.02
475th percentile
(41.53 mmol/l)
2.43 (1.47–4.04), Po0.001 2.41 (1.42–4.07), P=0.001
ADMA, asymmetrical dimethylarginine.
aReference group.
Table 4 | Multiple Cox regression analysis of plasma ADMA
for all-cause mortality and fatal and non-fatal CV events
All-cause mortality
Fatal and non fatal
cardiovascular events
Hazard ratio, 95% CI
and P-value
Hazard ratio, 95% CI
and P-value
Plasma ADMA
o50th percentile
(o0.95 mmol/l)
1a 1a
50–75th percentile
(0.95–1.53mmol/l)
1.72 (1.00–2.97), P=0.05 2.13 (1.24–3.65), P=0.006
475th percentile
(41.53 mmol/l)
3.11 (1.83–5.27), Po0.001 2.80 (1.63–4.81), P=0.001
Age (1 year) 1.06 (1.04–1.08), Po0.001 1.04 (1.02–1.06), Po0.001
Sex
(0=female;1=male)
2.11 (1.33–3.35), P=0.001 1.45 (1.00–2.27), P=0.05
ADMA, asymmetrical dimethylarginine.
aReference group.
Table 5 | Hill’s criteria for the inference of causality
Strength and the consistency of the observed relationship
Specificity of the observed link
Temporality (the cause should always precede the effect)
Biological gradient (a given relationship is more likely to underlie a causal
effect in the presence of a dose-response relationship)
Coherence
Unequivocal experimental evidence
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LVMI entailed a 35% increase in the death risk (hazard ratio:
1.35, Po0.001; Table 6).
As LVMI added a significant predictive power above and
beyond that provided by other risk factors (that is LVMI
significantly improved the prediction of prognosis in ESRD
patients), the conclusion of this paper was that measuring
LVMI may be useful for risk stratification in the ESRD
population. It is important noting that demonstrating that a
given risk factor adds predictive power to established
prognostic factors does not necessarily imply that the factor
is useful in clinical practice.9 Whether a prognostic factor is
useful depends on the magnitude of the additional
prognostic power it conveys and, most importantly, on the
demonstration that this information may improve the
clinical decision process in every day clinical practice.
Example 4. Prognostic scores or risk calculators may be
useful to refine prediction of clinical outcomes. For example,
risk calculators based on Framingham risk factors are
produced by the American and European society of
Cardiology. The INdividual DAta aNAlysis of antihyperten-
sive intervention trials (INDANA) risk calculator is a popular
instrument for predicting the 5-years risk of CV death in
adults with arterial hypertension (www.riskscore.org.uk).10
To build up this risk calculator, the INDANA investigators
identified by Cox regression analysis a series of factors that
were independently associated with the risk of CV death, that
is age, sex, current cigarette smoking, systolic pressure, total
cholesterol, creatinine, height, diabetes, left ventricular
hypertrophy, previous myocardial infarction, and previous
stroke. On the basis of Cox regression equation2:
Ht ¼ h0t eðb
ageþb1sexþb2smoking...etcÞ
a risk calculator was built up. This is a typical prognostic
model because it includes all factors that are predictive
without bothering whether they satisfy the criteria for
confounding or not. The application of this equation allows
the calculation of the individual risk by the simple
introduction into the same equation of the data defining
the risk factors profile, (that is age, sex, blood pressure, and
others) of the person wherein the risk estimate is being made.
For example the 5-year probability of CV death in an
individual with a risk profile detailed in Table 7 is 15.7%.
This is truly a high risk because it is six times higher than
that of a man of the same age without excess risk (2.6%).
This calculator is useful not only to formulate a prognosis
but also for patient education to reinforce treatment
recommendations. If a man with similar characteristics
lowers his blood pressure and stops smoking, his risk is
expected to decrease substantially.
CONCLUSION
The choice of the appropriate statistical modeling (etiological
vs prognostic model) is strictly dependent on the research
question being addressed and has important consequences on
model building, data analysis and data interpretation. In
etiological research control for confounding is fundamental.
In prognostic research the only thing that matters is the
accuracy of the prediction and therefore in this type of
research the nature (causal or non causal) of risk factors
being considered is irrelevant.
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Table 6 | Prognostic power of LVMI for all-cause mortality in
dialysis patients8
Units of increase
Hazard ratio
and 95% CI P-value
Unadjusted Cox regression analysis
LVMI (g/height2.7) 10 g/m2.7 1.45 (1.30–1.61) o0.001
Multiple Cox regression analysis
LVMI (g/height2.7) 10 g/m2.7 1.35 (1.22–1.63) o0.001
Age 1 year 1.05 (1.02–1.07) o0.001
Gender 0=female; 1=male 2.46 (1.45–4.18) o0.001
Cholesterol 1 mg/100 ml 1.01 (1.00–1.01) 0.002
Albumin 1 g/100 ml 0.41 (0.24–0.73) 0.002
Previous CV events 0=no; 1=yes 1.83 (1.15–2.90) 0.01
C-Reactive protein 1 mg/l 1.01 (1.00–1.01) 0.04
LVMI, left ventricular mass index; CV, cardiovascular.
Table 7 | INDANA risk calculator
Age 56 years
Sex Male
Current cigarette smoker Yes
Systolic blood pressure 170 mm Hg
Total cholesterol 250 mg/100 ml
Creatinine, if known 1.4 mg/100 ml
Height 170 cms
Does the patient have diabetes? No
Does the patient have left ventricular hypertrophy? Yes
Has the patient already had a myocardial infarction? No
Has the patient already had a stroke? Yes
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